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Purpose: The objective of this study was to determine if an oral ketamine mouth wash and
expectorant, that may or may not rinse transmucosal fentanyl, was a safe and effective
method to alleviate a series of various difﬁcult to control orofacial pain of cancer origin.
Materials and methods: A prospective review was made of the medical charts of 20 patients,
ﬁnding 8 patients who received ketamine mouthwash (40 mg = 4 ml), 8 patients who received
ketamine mouthwash and oral transmucosal fentanyl citrate 200 mcg, and 4 patients with
systemic opioids for refractory orofacial and mucositis pain.
Results: Of the 20 patients, 16 had orofacial or mucositis pain refractory to a mixture of
lidocaine and opioids. The effectiveness of ketamine mouthwash was 50% (8/16 patients).
The  combination of ketamine and/or fentanyl transmucosal had an analgesic efﬁcacy of
94.1%  (15/16 patients). The adverse effects were associated with the ketamine mouthwash;
all side effects were transient and subsided when the ketamine mouthwash was stopped.
Conclusion: Ketamine mouthwash for orofacial pain due to cancer may be an effective treat-
ment option. In cases of reported episodes of breakthrough pain, the combination of a
ketamine mouthwash and oral transmucosal fentanyl citrate may be a viable treatmentoption in refractory mucositis pain.
© 2013 SECOM. Published by Elsevier España, S.L.U. This is an open access article underthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A,  et al. Tratamiento con enjuagues de ketamina asociado o no a fentanilo transmucoso en el dolor oncológico orofacial resistente a
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Tratamiento  con  enjuagues  de  ketamina  asociado  o  no  a  fentanilo
transmucoso  en  el  dolor  oncológico  orofacial  resistente  a  opiáceos
mayores
Palabras clave:
Dolor orofacial
Dolor irruptivo oncológico
Cáncer
Mucositis
Ketamina
r  e  s  u  m  e  n
Objetivo: Evaluar la efectividad de los enjuagues de ketamina asociados o no a fentanilo
transmucoso en una serie de diversos dolores orofaciales de etiología neoplásica de difícil
control analgésico.
Material y métodos: Estudio prospectivo de 20 pacientes, con 8 pacientes que recibieron
enjuagues de ketamina (40 mg = 4 ml), 8 pacientes que recibieron ketamina asociada a
citrato de fentanilo por vía transmucosa oral a dosis de 200 mcg y 4 pacientes con opiáceos
sistémicos para el dolor orofacial y mucositis refractaria.
Resultados: Un total de16 de los 20 pacientes tenían dolor orofacial o mucositis refractaria
al  tratamiento con lidocaína y opiáceos. La tasa de éxito del empleo de enjuagues de keta-
mina fue del 50% (8/16 pacientes). La asociación ketamina y fentanilo transmucoso obtuvo
una tasa de éxito del 94,1% (15/16 pacientes). Los efectos adversos se asocian al uso de
la  ketamina; todos los efectos secundarios fueron transitorios y desaparecieron cuando se
suspendieron los enjuagues con ketamina.
Conclusión: Los enjuagues de ketamina son una opción eﬁcaz para el tratamiento del
dolor orofacial secundario al cáncer. En caso de presencia de episodios de dolor irruptivo
recurrente, la asociación de ketamina en enjuague bucal y citrato de fentanilo oral
transmucoso puede ser una opción viable en dolor refractario a otros tratamientos.
©  2013 SECOM. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access
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ain in patients with cancer has a high prevalence.1 Pain is an
ssential aspect of oncologic diseases that must be treated
s such, and its therapeutic management must be consid-
red a priority as important as the underlying disease, given
hat pain and uncontrolled pain crisis can be as devastat-
ng as the oncologic disease itself.2,3 Temporary ﬂare-ups
igniﬁcantly reduce patients’ quality of life and represent a
ifﬁcult therapeutic challenge for clinicians. The term break-
hrough pain was introduced by Portenoy and Hagen4 and it
s deﬁned as a sudden and temporary exacerbation of pain
xperienced on top of persistent, background, baseline pain
hat is stable and adequately controlled with major opioids.
n our country, this term was renamed “breakthrough cancer
ain” (BCP) based on an agreement document involving sev-
ral scientiﬁc associations.5 BCP may be incidental (related to
 speciﬁc triggering factor) or spontaneous. In several studies,
CP prevalence varies widely between 23% and 93%.6 Preva-
ence in Spain amounts to 41%, based on the study conducted
y Gómez-Batiste et al.7
There are different types of opioids based on their release
echanism and duration of their analgesic effect. In the
edical practice, the introduction of different rapid onset opi-
ids (ROO) with early stage maximum effects, short action
uration and reduced residual sedation episodes is an inter-
sting choice for the treatment of BCP. In our country,
everal pharmaceutical forms of ROO-type drugs are available
tablets with an integrated oral applicator, sublingual tablets,
ffervescent oral tablets, and transmucosal intranasal fen-
anyl). BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
On the other hand, topical treatments can control pain
locally, thus minimising systemic side effects. Therefore, sev-
eral agents administrated in mouthwashes in the oral cavity
for the treatment of oropharyngeal pain have been analysed.
These include local anaesthetics, antihistamines, anti-
inﬂammatory agents, opioids, n-methyl-d-aspartate (NMDA)
receptor antagonists, antimicrobial agents or combinations of
these. In general, results were mainly limited by the short
duration of pain relief obtained. NMDA receptors are widely
distributed along the nervous system, and the peripheral
administration of several NMDA receptor antagonist drugs
has several anti-inﬂammatory and antinociceptive actions.8,9
There are several routes of administration of ketamine
hydrochloride, which is an NMDA receptor antagonist.10–15
The objective of this study is to assess the effectiveness of
ketamine (KTM) mouthwashes associated or not with trans-
mucosal fentanyl (KTM + FENT) regarding several kinds of
neoplastic-aetiology orofacial pains which are difﬁcult to con-
trol with analgesics.
Materials  and  methods
Prospective, not randomised and descriptive study conducted
in a Chronic Pain Unit during 2008–2012 upon approval by the
Ethics Committee.
Inclusion criteria included the following: patients of age
with a histologically conﬁrmed cancer diagnosis and orofacial
pain symptoms attributable to neoplasia or complications
arising from its treatment, in patients receiving maintenance
treatment with opioids for chronic cancer pain. Table 1 shows
the classiﬁcation of mucositis used in our Unit. Maintenance
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Table 1 – Classiﬁcation of the grade of mucositis.
Grade Symptoms
Grade 0 No
Grade I Erythema
Grade II Erythema, ulcers without
odynophagia to solids
Grade III Erythema, ulcers without
odynophagia to liquids
Grade IV Erythema, ulcers with
odynophagia to liquids (need of
parenteral or enteral nutrition)
Grade V Exitus letalisSource: World Health Organisation.26
treatment is deﬁned as an opioid based treatment of at
least 60 mg  of oral morphine per day, 25 mcg  of transder-
mal  fentanyl per hour, 30 mg  of oxycodone per day, 200 mg
of tapentadol per day or an equianalgesic dose of any other
opioid during a week or more.
Exclusion criteria included the following: patients not of
age, with allergy or intolerance to ketamine hydrochloride,
fentanyl or any other opioids, with history of any kind of drug
addiction, uncontrolled high blood pressure, epilepsy, unsta-
ble ischaemic cardiopathy, cerebral expansive processes of any
aetiology and concomitant treatment with monoamine oxi-
dase inhibitors.
Ethical  considerations
The procedures carried out in this investigation complied
with the ethical standards of the Human Experimentation
Committee of our hospital and community, as well as the
guidelines of the World Medical Association and the Dec-
laration of Helsinki. Upon obtaining the informed consent
from patients regarding study participation and publication of
results, we have ensured the privacy and the conﬁdentiality of
patients.
Unit  protocol
All patients were subject to an initial opioid dose titration
stage, which involved increasing the opioid dose until pain
control was achieved or until the onset of signiﬁcant side
effects. In these cases, there was an opioid rotation with
subsequent dose adjustment and control of adverse effect re-
onset. In those cases with poor control of orofacial pain or
onset of adverse events, we  began treatment with 4 ml  of KTM
mouthwashes (10 mg/ml) during 4–5 min, and the degree of
pain relief and the number and degree of side effects was
assessed in this ﬁrst administration. In those cases with a
good analgesic response, families were offered 5–6 syringes
of the product to carry out instillations at home every 8 h.
At 72 h, patients were re-assessed. In cases where pain con-
trol and tolerance were considered appropriate, treatment at
home with KTM syrup 100 ml  (10 mg/ml) in Ora-Sweet, for-
mulated by the Hospital Pharmacy Service of our centre, was
prescribed. In cases with poor analgesic control or incidental
pain crisis onset during the administration interval, transmu-
cosal fentanyl 200 g was indicated. In cases with side effect f a c . 2 0 1 5;3  7(2):80–86
onset, the concentration of KTM was reduced to 5 mg/ml  and
transmucosal fentanyl was indicated.
The success of the treatment was deﬁned as pain relief
above 75% in an visual analogue scale (VAS) compared to base-
line VAS. Analgesic partial control was deﬁned as a reduction
in baseline pain of about 25–75%.
Variables
Several demographic variables, associated comorbidity, and
neoplasia type and stage were assessed, and diagnoses were
grouped based on the ICD-9 disease classiﬁcation system,
existence of previous surgery and type of surgery, local
and systemic adverse events (respiratory depression, circulatory
depression, low blood pressure, dizziness, drowsiness, headache,
nausea, vomiting, fatigue, vasovagal reaction, vision abnormalities,
rhinitis, abdominal pain, diarrhoea, constipation, dyspepsia, mouth
dryness, cutaneous eruption, itching, ﬂushing, hot ﬂushes, asthenia,
irritation in the injection site, anorexia, concentration difﬁculty and
euphoria), baseline analgesic medication, onset time of pain
symptoms, pain intensity based on an 11-point VAS, from 0 to
10 (where 0 is no pain and 10 is the worst imaginable pain), base-
line opioid dose, aetiology, topography and characteristics of
the pain.
After controlling the pain, the baseline opioid was progres-
sively reduced and, upon stabilising the dose, several of the
opioids used were converted to equianalgesic doses of mor-
phine to assess the reduction in opioid consumption. The
level of satisfaction of treatment administration was assessed.
Then, a telephone interview or a clinical history revision was
conducted to assess the progression 1, 3 and 6 months after
the beginning of the treatment.
Statistical  analysis
The statistical analysis was carried out using the Stata® 7 soft-
ware  (Stata Corporation, Computing Resource Centre, College
Station, Texas, U.S.A.). A descriptive analysis of the variables
was carried out, and the distribution of their frequencies was
calculated on a global scale. Normal distribution was assessed
using the Kolomogorov–Smirnov test, and the treatment suc-
cess and failure distribution was compared among patients of
the series as to observed variables and their possible associ-
ation using, for quantitative variables, the Student’s t test or
the Kruskall–Wallis test, if there were no equal variances, and,
for qualitative variables, the square chi test (Chi2) with Yates
correction or Fischer’s test. A new signiﬁcance level of p < 0.05
was determined for all statistical data used. The efﬁciency of
the different treatment options for cancer orofacial pain and
adverse events was assessed.
Results
The number of patients recruited during the study period
was  25, excluding, from the onset, 4 cases due to associated
medical comorbidity where KTM administration was con-
traindicated. After that, upon upward titration or rotation with
opioids, it was possible to achieve an adequate control of
pain without side effects in 4 cases, so the KTM protocol was
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25 patients with cancer orofacial chronic pain. Resistant to treatment with opioids
Visit to a chronic pain unit
Exclusion: 4 cases.
Exitus letalis: 1 case.
1. Unstable angor (2 cases).
2. Epilepsy (1 case).
3. Uncontrolled HBP (1 case).
21 patients with chronic pain. Major opioid dose adjustment.
Good analgesic control
with good tolerance
(4 cases).
Poor analgesic control.
(13 cases)
Oral ketamine mouthwashes.
(16 cases)
Good analgesic control.
(8 cases)
Good analgesic control.
(7 cases)
Partial analgesic control.
(8 cases)
Oral ketamine mouthwashes and transmucosal fentanyl.
(8 cases)
Good analgesic control
with poor tolerance
(3 cases).
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ot started. During follow-up, another patient was excluded
ue to exitus letalis during the study period. The ﬂow chart of
atients during follow-up and the causes of exclusion from
he study are shown in Fig. 1.
The study cohort was ﬁnally made up of 20 patients, of
hich 16 began the protocol with KTM mouthwashes. The
ean age of the cohort was 64.70 ± 16.37 years, mostly male
atients (75%). The main demographic characteristics of the
eries are shown in Table 2. Due to the study design, the base-
ine pain estimated using a VAS was of high intensity, with
alues around 8.25 ± 1.29 (6–10 range). Baseline opioid anal-
esic consumption at the beginning of the treatment with
TM or KTM + FENT mouthwashes was 224 ± 44 mg  of oral
orphine, which was reduced to 153 ± 41 mg  of oral morphine
p < 0.001). The decrease in opioid consumption was estimated
t 32%.
The success rate of KTM mouthwashes was 50% (8/16
atients). The KTM + FENT combination obtained a success
ate of 94.1% (15/16 patients). With both treatments, the
tart time of the analgesic effect was lower than 10 min. chart.
The main cause of KTM mouthwash failure was the onset of
BCP episodes. The KTM+FENT combination reduced the pre-
dictable BCP percentage from 75 to 12.5% (p = 0.016).
Fig. 2 shows variations in pain during 24 h and mean
pain prior to the beginning of the analgesic treatment. Fig. 3
shows the mean variation with standard deviation of the
treatment with KTM mouthwashes compared to the combi-
nation of KTM + FENT mouthwashes in cases of predictable
BCP (p < 0.001).
In most cases, adverse events were mild. Drowsiness,
dizziness, emesis symptoms and constipation were the most
common adverse events (Table 3). Patients considered respon-
dent to treatments based on systemic opioids presented a
greater number of adverse events and a progressive increase
in doses, but no statistically signiﬁcant differences. Thus, the
number of adverse events per patient was 6.5; 2.3 and 2.8 in the
group of patients treated with opioids, KTM mouthwashes and
KTM + FENT mouthwashes, respectively. In patients treated
with KTM and KTM + FENT mouthwashes, the most common
side effect was mild and temporary dizziness.
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Table 2 – Demographic characteristics of the clinical cases series.
N Age Gender Type of neoplasia RDT CMT Mucositis grade VAS Treatment
1 58 Male Lung cancer Yes Yes 3 6 Oxycodone
2 27 Female Myeloid leukaemia No Yes 4 8 Tramadol
3 75 Male Oesophageal cancer Yes No 3 8 Fentanyl
4 77 Male Tongue cancer Yes Yes 3 7 Fentanyl
5 77 Female Lung cancer Yes Yes 3 9 Fentanyl
6 46 Male Rectum cancer No Yes 3 9 Morphine
7 54 Male Tongue cancer No Yes 0 7 Fentanyl
8 76 Male Tongue cancer No Yes 0 8 Morphine
9 65 Male Oropharyngeal cancer Yes Yes 0 8 Morphine
10 68 Male Tongue cancer Yes Yes 3 10 Fentanyl
11 69 Male Trigone cancer No Yes 3 9 Fentanyl
12 38 Male Tongue cancer Yes Yes 1 10 Tapentadol
13 89 Male Tongue cancer No No 1 7 Fentanyl
14 59 Male Oropharyngeal cancer Yes Yes 2 10 Oxycodone
15 88 Female Tongue cancer No No 1 9 Oxycodone
16 67 Male Tongue cancer No Yes 1 8 Morphine
17 61 Male Tongue cancer Yes Yes 2 9 Oxycodone
18 65 Female Oropharyngeal cancer Yes Yes 1 10 Fentanyl
19 86 Female Tongue cancer No No 0 7 Fentanyl
20 49 Male Tongue cancer No Yes 0 6 Oxycodone
sitis VAS: baseline pain measurement using a visual analogue scale; muco
chemotherapy treatment; RDT: radiotherapy treatment.
Discussion
The main ﬁnding of this study is that KTM mouthwashes have
a very rapid analgesic effect and are highly effective for the
control of oral cavity pain in cancer patients and in mucositis
cases, thus reducing pain at rest and during activities, such as
eating, sneezing or yawning. It is possible to speculate that, in
certain patients and under certain circumstances, this would
be a treatment option for patients with orofacial pain resistant
to several treatments, without it being associated with signif-
icant adverse events. The agreed use of KTM mouthwashes
Table 3 – Adverse events of the different treatment options.
Adverse events Opioids KTM 
No. of cases 4 8 
Constipation 3 (75) 1 (12.5) 
Drowsiness 4 (100) 2 (25) 
Concentration difﬁculty 3 (75) 1 (12.5) 
Dizziness 3 (75) 3 (37.5) 
Nausea or vomiting 4 (100) 1 (12.5) 
Dyspepsia 1 (25) 2 (25) 
Mouth dryness 2 (50) 2 (25) 
Anorexia 4 (100) 4 (50) 
Cutaneous irritation 2 (50) 1 (12.5) 
Euphoria 0 2 (25) 
BCP episodes
≤1 0 1 
>1 4 7 
Total 26 19 
One patient may present more than one adverse event. Data expressed in
during the follow-up period are recorded.
Used statistical analysis: chi-square test (Chi2) with Yates correction or Fis
BCP: breakthrough cancer pain (not recorded as adverse events).grade: classiﬁcation of the grade of mucositis; N: case number; CMT:
during several months led to a rapid decrease in symptoms, a
signiﬁcant improvement in quality of life, a high level of sat-
isfaction and a reduction in the use of opioid analgesics and
several neuromodulator drugs.
In our series, KTM mouthwashes act as an excellent base-
line analgesic with good tolerance. Its main disadvantage is
that, in a signiﬁcant percentage of patients (50% of the cases),
it does not control BCP episodes. This BCP represents a sig-
niﬁcant clinical problem which may have a huge impact on
patients’ quality of life because it alters the sleep-wakefulness
cycle, sleep, emotional health, personal relations and sev-
eral daily activities.16 In our cases, these orofacial pains were
KTM + FENT Total p
8 20 –
2 (25) 6 0.353
3 (37.5) 9 0.361
2 (25) 6 0.353
4 (50) 10 0.879
2 (25) 7 0.170
2 (25) 5 0.532
2 (25) 6 0.899
1 (12.5) 9 0.361
2 (25) 5 0.725
3 (37.5) 5 0.806
7 8 0.016
1 12
23 68 0.213
 number of cases and percentage. All adverse events which occurred
cher’s test.
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Fig. 2 – Measurement of pain and episodes of breakthrough
cancer pain using a visual analogue scale based on
treatment with ketamine hydrochloride mouthwashes
compared to ketamine hydrochloride and transdermal
fentanyl mouthwashes as to baseline pain upon admission
to the Unit.
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of satisfaction when using a therapy that controlled pain in
4–5 min.
The action mechanism of the KTM mouthwash analgesic
effect is not well-known. It could be associated with transmu-
cosal absorption of ketamine or the involuntary swallowing of
mouthwash. Clements et al. determine that ketamine plasma
levels necessary to obtain an analgesic action after intra-
venous bolus are approximately 100 ng/ml.18 Analgesic effects
after its oral administration are below 40 ng/ml, presumably
due to high levels of norketamine (160 ng/ml). We did not mea-
sure plasma levels of ketamine, but the Canbay study,19 after
the administration of 40 mg  of mouthwash, detected maxi-
mum concentrations of ketamine and norketamine in 16.16
and 11.43 ng/ml, respectively. These low levels suggest that it
is highly unlikely that systemic absorption played an impor-
tant role in the reduction of pain and, therefore, a topical effect
per se is possible.
A correlation between the analgesic effect and NMDA
complex seems more  likely. Glutamatergic routes are widely
involved in excitatory neurotransmission, including nocicep-
tion. Glutamate receptor groups are found in the central
nervous system and in the nervous ﬁbres of peripheral
tissue20,21 and, therefore, the peripheral blockage of recep-
tors may be a promising option. It is not possible to rule out
that the analgesic effect and nervous blockage, such as local
anaesthetics, of these sub-anaesthetic doses are due to their
activity on several opioid receptors, monoaminergics, mus-
carinics and calcium and sodium ionic channels.22 The clinical
use of KTM is limited due to its psychotomimetic and car-
diovascular adverse events, such as high blood pressure and
tachycardia, though their incidences are materially reduced
when administered in low doses. In our series, the use of
KTM mouthwashes was not associated with haemodynamic
effects, but with mild and temporary psychotomimetic effects
during initial uses of the mouthwash. We  have not observed
gastric, vesical, renal or hepatic effects due to its chronic use.
Our results match those obtained in published studies
assessing the use of ketamine mouthwashes, and they show a
high rate of effectiveness in several cases of orofacial pain. The
group of Ryan et al.23 presents a retrospective study conducted
in 8 patients with ketamine mouthwash for the treatment of
refractory pain due to oral mucositis, with a 62% success rate.
Slatkin et al.24 describe the successful use of oral topical KTM
for the treatment of oral mucositis pain in a female patient
with tongue carcinoma subject to radiotherapeutic treatment.
Other studies show similar results.25
The adequate KTM mouthwash dosage is unknown. In the
cases that we presented, the initially used dose is 40 mg  in
each mouthwash, similar to that used in previously men-
tioned studies (20 or 40 mg  per mouthwash). In our series,
the KTM+FENT combination for several daily activities, mainly
chewing, led to a better control of pain in a subgroup of
patients with oral intake improvement. We have not currently
started to reduce the dose in order to determine the mini-
mum efﬁcient dose. However, since the doses mentioned in
this study are considered effective and present no side effects,
it was decided to maintain these regimes. In future studies,
it should be established if pain relief is dose-dependent, opti-
mum doses should be determined and it should be understood
how important the matrix is for its administration and if this
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could interfere with its topical effect. We used a dilution in
Ora-Sweet® syrup which contains 70% sucrose, 6% glycerine
and 5% sorbitol, while other authors have used a solution con-
sisting of artiﬁcial saliva and physiological saline serum.
Conclusion
The KTM mouthwash used for the treatment of orofacial pain
secondary to cancer is an effective, low cost therapeutic option
with few side effects. In cases where there are incidental BCP
episodes, the KTM + FENT combination is a more  advisable
therapy. More  studies are needed to verify these results and
to titre the optimum dose since not enough bibliography on
this therapy has been published.
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